Mckesson Corporation

NYSE: MCK
$579.74
+$0.52 (+0.1%)
Closing Price on December 20, 2024

MCK Stock Chart and Intraday Price

MCK Stock Data

Asset Type Stock
Exchange NYSE
Currency USD
Country USA
Sector TRADE & SERVICES
Industry WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
Address 6555 STATE HIGHWAY 161, IRVING, TX, US
Fiscal Year End March
Latest Quarter 12/31/2023
Market Cap 69,104.84M USD
Shares Outstanding 131,408,000
Mckesson Corporation is a global healthcare services provider, offering a wide range of products and services. Its operations span across pharmaceutical distribution, including branded, generic, and specialty drugs, as well as over-the-counter products. The company also delivers technology solutions for pharmacies, practice management, and clinical support to specialty practices. Additionally, Mckesson plays a crucial role in connecting various healthcare stakeholders, such as patients, pharmacies, and biopharma companies, through its Prescription Technology Solutions. It further supports healthcare providers with medical-surgical supplies and logistics. Founded in 1833, Mckesson is headquartered in Irving, Texas, serving customers in the U.S. and internationally.

MCK Articles

These four Jim Cramer stock picks had strong November performances and are likely to follow through in December.
Selecting stocks for the long haul can be a challenge. Here is what could be the best-performing stock in 2030 and why.
While dividend stock investing is one of the best strategies an investor can pursue to create phenomenal wealth, chasing yield can undermine the entire effort. Buying dividend stocks simply because...
These five top companies are Wall Street favorites and are expected to raise their dividends this week, showing that they are doing well and have the earnings and cash flow strength to increase their...
Monday's top analyst upgrades and downgrades included BlackBerry, Cardinal Health, Comstock Resources, Howmet Aerospace, JD.com, Pacific Biosciences of California, Restaurant Brands, Tenaris and...
Wednesday's top analyst upgrades and downgrades included Altria, Apple, Bath & Body Works, BorgWarner, Chevron, Exxon Mobil, FedEx, Occidental Petroleum, Peabody Energy, Plug Power, Rio Tinto,...
Monday's top analyst upgrades and downgrades included Bill.com, Cigna, ConocoPhillips, Estee Lauder, Fortinet, Microchip Technology, Pfizer, Skyworks Solutions, Snap, Snowflake, VICI Properties and...
Monday's top analyst upgrades and downgrades included Airbnb, AT&T, Duke Energy, Etsy, FirstEnergy, Gap, IBM, KeyCorp, Kohl's, Las Vegas Sands, Nvidia, Starbucks, Trade Desk and Visa.
In a move that investors looking for more defensive ideas should applaud, the analysts at Goldman Sachs have added Bristol-Myers Squibb to the Americas Conviction List. Plus, here are four additional...
Monday's top analyst upgrades and downgrades included AbbVie, Alibaba, Archer Daniels Midland, Best Buy, Intel, Nikola, Peloton Interactive, SAP, Under Armour and Wynn Resorts.
Tuesday's top analyst upgrades and downgrades included Charter Communications, Clorox, FirstEnergy, Neurocrine Biosciences, RingCentral, Roku, Seagate Technology, Take-Two Interactive Software and...
The Goldman Sachs analysts feel these five companies could see direct benefits from the movement of supply chains and manufacturing out of Asia, specifically China.
Many hospitals shut down elective surgeries and other activities to brace for the impact of COVID-19. However, analysis on these shutdowns is yielding some interesting insight.
These four blue chip large-cap stocks have taken a beating this year and all offer patient investors the potential for some big upside.
Johnson & Johnson is trading higher on the news, but some smaller public companies tied into the opioid crisis are taking it on the chin.